Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

49.23USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$49.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
302,053
52-wk High
$67.10
52-wk Low
$17.74

Latest Key Developments (Source: Significant Developments)

Portola Provides Update On European Marketing Authorization Application For Betrixaban
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Portola Pharmaceuticals Inc ::PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN.CHMP OF EMA HAS REQUESTED ADDITIONAL INFORMATION RELATED TO MARKETING AUTHORIZATION APPLICATION (MAA) FOR BETRIXABAN.CHMP OF EUROPEAN MEDICINES AGENCY REQUESTED MORE INFORMATION RELATED TO MARKETING AUTHORIZATION APPLICATION (MAA) FOR BETRIXABAN.PORTOLA PHARMA SAYS CHMP HAS PROVIDED DAY 195 LOOI TO CO WITH REQUEST FOR RESPONSES DURING NEXT AVAILABLE SUBMISSION WINDOW OF JAN 23, 2018.EXPECTS CHMP TO ISSUE AN OPINION ON BETRIXABAN LATER IN Q1 OF 2018..  Full Article

Portola Pharmaceuticals provides update on Bevyxxa commercial launch
Tuesday, 21 Nov 2017 06:22pm EST 

Nov 21 (Reuters) - Portola Pharmaceuticals Inc ::Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch.FDA extended review period for co's prior approval supplement for Bevyxxa to allow agency time to review entire submission​.‍FDA said it will respond to PAS request to change current manufacturing release specification within 60-day extension period​.New action date for Bevyxxa is January 30, 2018​.  Full Article

Portola announces pricing of public offering of common stock at $55 per share
Tuesday, 12 Sep 2017 10:39pm EDT 

Sept 12 (Reuters) - Portola Pharmaceuticals Inc - :Portola announces pricing of public offering of common stock.Portola Pharmaceuticals-announced today pricing of underwritten public offering of 6.3 million shares of its common stock at a price of $55.00 per share.Co will not be presenting at 2017 Morgan Stanley Global Healthcare Conference.  Full Article

Portola Pharma announces proposed offering of common stock
Monday, 11 Sep 2017 04:01pm EDT 

Sept 11 (Reuters) - Portola Pharmaceuticals Inc :Portola Pharmaceuticals announces proposed offering of common stock.Portola Pharmaceuticals Inc says ‍plans to offer, $300 million of its common stock in an underwritten public offering​.  Full Article

Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018
Tuesday, 15 Aug 2017 08:00am EDT 

Aug 15 (Reuters) - Portola Pharmaceuticals Inc :Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA.‍Action due date for review of BLA for Andexxa (Andexanet Alfa)​ is February 2, 2018.  Full Article

Portola Pharmaceuticals reports Q2 loss per share of $1.22
Wednesday, 9 Aug 2017 04:25pm EDT 

Aug 9 (Reuters) - Portola Pharmaceuticals Inc :Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $1.22.Q2 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Portola Pharmaceuticals ‍qtrly ‍collaboration and license revenue $3.8 million versus $4.2 million.  Full Article

Portola announces resubmission of BLA for Andexxa
Thursday, 3 Aug 2017 04:13pm EDT 

Aug 3 (Reuters) - Portola Pharmaceuticals Inc :Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa).Portola Pharmaceuticals Inc- ‍resubmission includes supplemental information primarily related to manufacturing, as requested by FDA​.Portola pharmaceuticals - ‍resubmitted biologics license application to center for biologics evaluation and research of U.S. FDA for Andexxa​.  Full Article

Portola Pharmaceuticals says U.S. FDA approves blood-thinner Bevyxxa to prevent clots
Friday, 23 Jun 2017 01:04pm EDT 

June 23 (Reuters) - Portola Pharmaceuticals Inc : :U.S. FDA approves Bevyxxa® (Betrixaban) first and only anticoagulant for hospital and extended duration prevention of Venous Thromboembolism (VTE) in acutely ill medical patients.Portola Pharmaceuticals Inc- Timeline on which portola expects to launch Bevyxxa is between August and November 2017.  Full Article

Portola Pharmaceuticals reports Q1 loss per share $0.74
Monday, 8 May 2017 04:36pm EDT 

May 8 (Reuters) - Portola Pharmaceuticals Inc :Portola Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.74.Q1 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Portola Pharmaceuticals Q4 loss per share $0.95
Tuesday, 28 Feb 2017 04:05pm EST 

Portola Pharmaceuticals Inc : Portola Pharmaceuticals reports fourth quarter and year-end 2016 financial results and provides corporate update . Q4 loss per share $0.95 . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S . For fiscal year 2017, portola expects total gaap operating expenses to be between $323 million and $344 million .Portola pharma - for fiscal year 2017, expects total pro-forma operating expenses to be between $290 million & $310 million, excluding stock-based compensation.  Full Article

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN